Gelonghui on September 27th | Clover vaccine (6660.HK) soared more than 43% at the beginning of trading, reaching a high of 6.4 Hong Kong dollars. On the news front, Clover vaccine announced that it will participate in CPHI Milan, the world's largest pharmaceutical industry professional exhibition held in Milan, Italy from October 8th to 10th, 2024. It is reported that currently, Clover already owns four wholly owned holding vaccine production companies and three central vaccine research institutes. It is one of the first two human vaccine companies in the country granted permission to build Level 3 biosafety laboratories in the 14th Five-Year Plan. It is also the world's largest manufacturer of hepatitis B vaccines and the world's second largest manufacturer of rabies vaccines. Clover has 8 commercialized vaccines and 21 vaccines in research, with a pipeline covering the top ten vaccine varieties globally. The commercialized products already hold a leading position in the market, with sales covering all 31 provinces, municipalities, and autonomous regions in China, reaching over 2,000 district-level centers for disease control.